{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BiomX, Inc.
Is BiomX, Inc. technically bullish or bearish?
As of May 28, 2025, BiomX, Inc. is in a bearish trend with moderate strength, driven by bearish daily moving averages and indicators, despite some mildly bullish signals in the weekly and monthly MACD.
Who are in the management team of BiomX, Inc.?
As of March 2022, the management team of BiomX, Inc. includes Dr. Russell Greig (Independent Chairman), Mr. Jonathan Solomon (CEO), and several independent directors: Dr. Gbola Amusa, Mr. Jonas Grossman, Dr. Alan Moses, Mr. Paul Sekhri, and Ms. Lynne Sullivan. They are responsible for the company's strategic direction.
What does BiomX, Inc. do?
BiomX, Inc. is a microbiome company specializing in natural and engineered phage therapies in the Pharmaceuticals & Biotechnology sector. As of March 2025, it has a market cap of $10.21 million and reported a net profit loss of $8 million.
How big is BiomX, Inc.?
As of Jun 18, BiomX, Inc. has a market capitalization of 10.21 million, with net sales of 0.00 million and a net profit of -16.15 million over the latest four quarters. Shareholder's funds are at 24.15 million, and total assets amount to 98.81 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
